AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1496226
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy following lumpectomy
Trial: 1496226
Drug: No radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No radiation therapy following lumpectomy
Trial: 1496226
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy following IBTR
Trial: 6196251
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (10 patients)
Trial: 26882332
Drug: Behavioral parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral parent training (8 group sessions) and brief teacher consultation to establish a Daily Report Card
Trial: 26882332
Drug: Extended‐release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended‐release methylphenidate (equivalent to .15 mg/kg/dose bid)
Trial: 25030943
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg intramuscularly immediately after ERCP
Trial: 12598340
Drug: S16020 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S16020 (80 or 100 mg/m2, 3‐h infusion every 3 weeks)
Trial: 12598340
Drug: Methotrexate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (40 or 50 mg/m2, bolus injection weekly for a minimum of 6 weeks)
Trial: 8739138
Drug: Local antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antifungal agent (miconazole, 2% gel) for 4 weeks
Trial: 8739138
Drug: Systemic antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antifungal agent (fluconazole, 50 mg) for 2 weeks
Trial: 25283470
Drug: Milnacipran (serotonin-norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (serotonin-norepinephrine reuptake inhibitor)
Trial: 23392399
Drug: ICAM-1 (intercellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICAM-1 (intercellular adhesion molecule 1)
Trial: 23392399
Drug: VCAM-1 (vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCAM-1 (vascular cell adhesion molecule 1)
Trial: 23392399
Drug: TNF-α receptor
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α receptor 1 (tumor necrosis factor α receptor 1)
Trial: 20927577
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) group
Trial: 18171181
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hand gel)
Trial: 17139600
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with inhaled iloprost and bosentan
Trial: 17139600
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with inhaled iloprost and sildenafil
Trial: 17139600
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with bosentan and sildenafil
Trial: 17139600
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with two or three of the mentioned drugs
Trial: 11070991
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of somatostatin analogues
Trial: 11070991
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists (e.g., bromocriptine)
Trial: 8865083
Drug: Control clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control clamp (CC)
Trial: 6861871
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine tablets (20-40 mg every 4 to 6 hours)
Trial: 6861871
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine solution (20-40 mg every 4 to 6 hours)
Trial: 30501629
Drug: In-clinic physical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic physical therapy focused on strengthening
Trial: 30501629
Drug: In-clinic physical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic physical therapy containing placebo
Trial: 26770048
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (group D)
Trial: 25264782
Drug: Biojector IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biojector IM injection of rAd5 vaccine at 10^10 PU
Trial: 25264782
Drug: Needle injection
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle injection of rAd5 vaccine at 10^10 PU
Trial: 25264782
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of rAd5 vaccine
Trial: 25264782
Drug: Biojector delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biojector delivery of rAd5 vaccine
Trial: 22419732
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg plus pioglitazone (any dose)
Trial: 22419732
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg plus pioglitazone (any dose)
Trial: 2392794
Drug: Transcricoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcricoid injection of 100 mg lignocaine
Trial: 2392794
Drug: Spray as
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray as you go technique with 240 mg lignocaine
Trial: 373777
Drug: Ambroxol 45
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 45 mg/d
Trial: 373777
Drug: Bromhexine 36
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 36 mg/d
Trial: 27726423
Drug: Intralesional steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroids (8 mg of dexamethasone plus 2 mL of lidocaine)
Trial: 27726423
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (3 mL of PRP activated with 0.45 mL of 10% calcium gluconate)
Trial: 1535020
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate depot 3.75 mg injected every 24 days
Trial: 1535020
Drug: Danazol 600-800
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 600-800 mg daily
Trial: 31743424
Drug: Optimal individualized
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal individualized treatment regime (ITR) using data from a 2 × 2 crossover study
Trial: 20609226
Drug: Sequential medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential medium (group A)
Trial: 18711172
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) 4 mg intravenously every 3 months for 1 year
Trial: 14962261
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with etoposide 80 mg/m² and thioguanine 100 mg/m² twice daily on 5 days and idarubicin 15 mg/m² on 3 days (ETI)
Trial: 14962261
Drug: Intravenous combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous combination of cytarabine 100 mg/m² twice daily on 5 days, idarubicin 12 mg/m² x 1, and thioguanine (TAI)
Trial: 11422429
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (12 U) injected into the carpal tunnel weekly for 7 weeks
Trial: 11422429
Drug: Placebo injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected into the carpal tunnel weekly for 7 weeks
Trial: 9422907
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia administered before tooth removal
Trial: 9422907
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia administered after tooth removal
Trial: 8387410
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of tetravalent reassortant rhesus rotavirus vaccine (4 x 10(4) PFU)
Trial: 8387410
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of tetravalent reassortant rhesus rotavirus vaccine (4 x 10(5) PFU)
Trial: 8387410
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of tetravalent reassortant rhesus rotavirus vaccine
Trial: 8387410
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of tetravalent reassortant rhesus rotavirus vaccine
Trial: 29933718
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (100 mg per day for 12 weeks)
Trial: 29933718
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg cellulose acetate per day for 12 weeks)
Trial: 27733521
Drug: High-amylose maize
RxNorm normalized name: hydroxypropyl distarch phosphate, high amylose corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-amylose maize resistant starch type 2 (HAM-RS2) bagel (25 g/d)
Trial: 20804058
Drug: Hypotensive anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotensive anesthesia (induced by speeding up propofol injection and maintaining general anesthesia at 4.4-9 mg/kg x hr)
Trial: 14723093
Drug: Evra patch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evra patch, worn for 7 days
Trial: 14723093
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs), taken daily
Trial: 11010941
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Fe/d as ferrous sulfate for 12 weeks
Trial: 8772471
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydrocortisone (oral administration)
Trial: 8772471
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms of corticotropin-releasing hormone (intravenous administration)
Trial: 6229735
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg/day)
Trial: 29992869
Drug: Treatment (home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (home visiting program 'Pro Kind')
Trial: 22814850
Drug: LiRIS 200
RxNorm normalized name: IRIS TENAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS 200 mg
Trial: 22814850
Drug: LiRIS 650
RxNorm normalized name: IRIS TENAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS 650 mg
Trial: 22814850
Drug: LiRIS 200
RxNorm normalized name: IRIS TENAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS 200 mg and 650 mg
Trial: 20632059
Drug: Topical 0.4%
RxNorm normalized name: fluoride topical 0.4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.4% glyceryl trinitrate (GTN) treatment for 40 days
Trial: 20632059
Drug: Topical 0.4%
RxNorm normalized name: fluoride topical 0.4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.4% glyceryl trinitrate (GTN) treatment for 80 days
Trial: 20632059
Drug: Topical 0.4%
RxNorm normalized name: fluoride topical 0.4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.4% glyceryl trinitrate (GTN) treatment (both groups)
Trial: 17846259
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (sertraline, 50-200 mg daily)
Trial: 11476360
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (HR)
Trial: 9836002
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (low dosage)
Trial: 9836002
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (high pharmacologic dosage)
Trial: 2971504
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dose of depot‐medroxyprogesterone acetate (DMPA)
Trial: 2971504
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg dose of depot‐medroxyprogesterone acetate (DMPA)
Trial: 23541417
Drug: CC and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC and rFSH (group B)
Trial: 23541417
Drug: CC and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC and hMG (group A)
Trial: 20668943
Drug: Phenylalanine (Phe)
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylalanine (Phe) loading test (100 mg/kg)
Trial: 18840367
Drug: Amlodipine/Ramipril combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Ramipril combination therapy (mean dose 7.60/7.60 mg)
Trial: 18840367
Drug: Amlodipine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine monotherapy (mean dose 7.97 mg)
Trial: 18840367
Drug: Amlodipine/Ramipril combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Ramipril combination therapy
Trial: 16880243
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) administered via a 15-minute infusion every 3 or 4 weeks for 12 infusions
Trial: 12818279
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg NT‐3 three times per week (TTW)
Trial: 15612515
Drug: Glimepiride (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (up to 4 mg)
Trial: 15612515
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (4 mg glimepiride plus 2 g metformin)
Trial: 9971866
Drug: Thyroxine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine alone (usual dose)
Trial: 25816110
Drug: High-dose Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Losartan (High-Los)
Trial: 15517668
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin chloride 10 mg (qd)
Trial: 15517668
Drug: Tolterodine tartrate
RxNorm normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine tartrate 4 mg (2 mg bid)
Trial: 2967624
Drug: Control solutions
RxNorm normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solutions of oxygenated Ringer's lactate and nonoxygenated FDA-20
Trial: 17964396
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) in combination with sodium hyaluronate 1% (Provisc)
Trial: 15140340
Drug: Testosterone buccal
RxNorm normalized name: testosterone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone buccal system (Striant), 30 mg twice daily
Trial: 15140340
Drug: Transdermal gel
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal gel delivery system (T‐gel), AndroGel 5 g containing 1% (50 mg) T, daily for 14 days
Trial: 15140340
Drug: Testosterone buccal
RxNorm normalized name: testosterone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone buccal system
Trial: 15140340
Drug: Transdermal gel
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal gel delivery system (T‐gel)
Trial: 7649646
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment from an inactive machine
Trial: 2502843
Drug: Deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl (10 mg/day)
Trial: 30552041
Drug: Nicotine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (7 mg dermal patch)
Trial: 30552041
Drug: Atomoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (60 mg per os)
Trial: 27146248
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of lipid-based nutrient supplements plus malaria and diarrhoea treatment from age 9 to 18 months
Trial: 27146248
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of lipid-based nutrient supplements plus malaria and diarrhoea treatment
Trial: 26088659
Drug: Atomoxetine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine alone or with a stimulant
Trial: 26088659
Drug: Antipsychotic usually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic usually together with a stimulant
Trial: 26088659
Drug: Other pharmacotherapy
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other pharmacotherapy
Trial: 26088659
Drug: Indicated ADHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicated ADHD medication
Trial: 26088659
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic
Trial: 22188761
Drug: ARA-enriched oil
RxNorm normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA-enriched oil (240 or 720 mg ARA per day)
Trial: 19395188
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiotherapy (EBRT) plus androgen deprivation therapy
Trial: 10905544
Drug: Daily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fish meals
Trial: 8163889
Drug: 0.2% hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% hydrocortisone and 1.0% lignocaine hydrochloride no-touch aqueous spray
Trial: 3098573
Drug: Ritanserin (serotonin-S2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (serotonin-S2 antagonist), administered for five days
Trial: 31304380
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (six individual physiotherapy sessions over 6 weeks and high-quality online education)
Trial: 29924421
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo exposure group treatment
Trial: 20104528
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (ascorbic acid 120 mg, vitamin E 30 mg, beta‐carotene 6 mg, selenium 100 microg, zinc 20 mg)
Trial: 15272923
Drug: Raloxifene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (180 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (R‐Exp)
Trial: 15272923
Drug: Clomiphene (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene (150 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (Cl‐Exp)
Trial: 15272923
Drug: E2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 treatment in Group 2 (30 days) plus R from days 21 to 30 (R‐Exp)
Trial: 15272923
Drug: E2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 treatment in Group 2 (30 days) plus Cl from days 21 to 30 (Cl‐Exp)
Trial: 11434469
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser (LPL) therapy